Orders -2%, sales +1%, EBITA -18% vs. ABGSCe Unspecified non-recurring items related to improvement ...
Redeye comments on Freemelt’s Q3 results, which were roughly in line with expectations in terms of s...
NoHo Partners reported Q3 EBIT of EUR 9.9m (+14% y/y), 5% below Vara Research consensus and 11% belo...
Redeye provides an initial comment on the Q3 2024 report from Cheffelo, which came in below our esti...
Redeye updates on Gentoo Media after its pre-announced Q3-results which was close to our forecast wh...
Redeye initiates coverage of Jumpgate, a gaming company focused on PC and Console.
Redeye provides a short comment on the announcement of two orders, totalling SEK9.
IRLAB’s Q324 results highlighted progress across its clinical pipeline.
AVTECH announced it signed Iberojet, a Charter airline with seven aircraft.
Cyberattack impact on sales likely ~SEK 5-10m We cut '24e-'26e sales by 1% '25e-'26e EV/EBIT 21x-10x...
Redeye comments on Medivir’s clinical trial and supply agreement with Eisai.
While the Q3’24 report did not contain any particular surprises in terms of financials, it did provi...
Redeye initiates coverage of MedCap, a serial acquirer of niche life science SMEs that has posted st...
Redeye makes some revisions based on the Q3 report.
European improvements in H2e key for recovery, but risk remains A miss in Q3 would likely trigger a ...
Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of B...
Exel’s Q3 figures disappointed due to the continued demand softness, however EBIT has plenty of pote...
Etteplan’s Q3 was weak as was expected after the two profit warnings the company gave prior to the r...
Redeye states Gapwaves delivered strong numbers that beat Redeye Research estimates (RRe) and consen...
Redeye provides an update following CLS’s Q3 2024 report.
